OncLive Staff

Articles

Hasanuma Highlights the Benefits of Building Authentic Connections Through Mentorship

October 19th 2023

Dr Hasunuma shares that the objective of mentorship is to foster care, trust, and respect in mentor-mentee relationships and create authentic connections.

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

October 16th 2023

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

New Data Bring Excitement, Raise Questions in Advanced RCC

October 16th 2023

Although renal cell carcinoma remains a difficult-to-treat disease, with patients with clear cell histology experiencing a median overall survival of approximately 13 months and a 5-year overall survival rate of less than 10%, updated results from clinical trials examining emerging therapeutic strategies have spurred optimism.

Gutierrez and Leslie Discuss Recent Efforts and Future Advances in CAR T-Cell Therapy

October 12th 2023

Drs Gutierrez and Leslie discuss common barriers that institutions face when implementing CAR T-cell therapy programs, the early success story of outpatient administration of this modality at John Theurer Cancer Center, and future considerations for using this treatment approach in solid tumors.

Expert Insights on the United States Chemotherapy Shortage

October 9th 2023

Oncology experts discuss the platinum chemotherapy shortage in the United States.

FDA Approval Insights: First-Line Luspatercept for Anemia in Lower-Risk MDS

October 5th 2023

Dr Platzbecker discusses the FDA approval of luspatercept in lower-risk myelodysplastic syndrome with anemia; key efficacy and safety data from the COMMANDS trial; and how this approval addresses historically unmet needs for this population.

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023

Dr Richardson discusses the background of mezigdomide, key efficacy and safety findings with the agent plus dexamethasone in patients with relapsed/refractory multiple myeloma, and the implications of this combination for heavily pretreated patients in this population.

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

September 28th 2023

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.

Multidisciplinary Approaches Shape Treatment Pathways in EGFR-Mutated NSCLC

September 26th 2023

Emerging data in the neoadjuvant setting and the expansion of testing in standard practice have presented questions surrounding screening for and developing strategies from variant information in EGFR-mutated resectable non–small cell lung cancer.

Camidge and Garon Reflect on the Nuances of Career Development Through Clinical Research

September 25th 2023

In this episode of How This Is Building Me, Drs Camidge and Garon discuss the importance of continuing to ask a variety of research questions throughout one’s career; the value of negative study results; and the ins and outs of running the lung cancer program and conducting phase 3 clinical trials at UCLA.

NY Lung Seeks to Bridge Gaps in Lung Cancer Decision-Making

September 23rd 2023

The 18th Annual New York Lung Cancers Symposium, scheduled for November 11, 2023, as a live meeting in New York, New York, boasts an agenda that covers a broad range of modern clinical topics.

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Thoracic Clinical Expert Looks at Optimal Ways to Translate Data Into Practice

September 20th 2023

As oncogene-driven therapies move into clinical practice, it is paramount that clinicians have the tools and understanding to integrate the latest evidence for the appropriate treatment of patients with lung cancer.

Optimizing Treatment Strategies in the Evolving HR+/HER2- Breast Cancer Paradigm

September 19th 2023

Over the past 10 years, data from studies including the TAILORx and RxPONDER studies have reshaped treatment standards for patients with hormone receptor–positive, HER2-negative breast cancer.

Jones and Somaiah Review the Rationale and Design of the Peak Trial in GIST

September 18th 2023

Drs Jones and Somaiah discuss unmet needs in GIST that the Peak trial seeks to answer; the advantages of the methods and design of this trial; and how the tolerable safety profile of bezuclastinib plus sunitinib supports further research with this combination.

Novel PROTAC May Usher in New Class of Drugs for ESR1+, ER+/HER2– Breast Cancer

September 18th 2023

The development of novel next-generation hormonal agents is poised to change the landscape for patients with estrogen receptor-positive, HER2-negative breast cancer, offering additional oral solutions to lessen the burden of the invasive delivery of the standard of care and provide agents that are active against acquired variants.

Chuong Discusses the Importance of MRI-Guided Radiotherapy in Cancer

September 14th 2023

Dr Chuong discusses the evolution of MRI-guided radiation in the cancer treatment armamentarium, the benefits of the MRIdian SMART system, and how Miami Cancer Institute is leading the way with trainings to expand the use of this technology.

Fonkoua Sheds Light on Liver Cancer Clinical Trial Disparities

September 11th 2023

Dr Fonkoua discusses the ways in which common clinical trial enrollment criteria in oncology exclude patients from underrepresented groups, enrollment disparities that uniquely affect patients with liver cancer, and initiatives that Mayo Clinic is participating in to eliminate barriers to clinical trial enrollment.

FDA Approval Insights: Talquetamab in Relapsed/Refractory Multiple Myeloma

September 7th 2023

Dr Minnema discusses the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma, key data from the MonumenTAL-1 trial, and the importance of designing clinical trials to address unmet patient needs.

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.